MONTREAL, QUEBEC -- (MARKET WIRE) -- December 04, 2006 -- MethylGene Inc. (TSX: MYG) today announced clinical results for its isotype-specific, histone deacetylase (HDAC) inhibitor, MGCD0103, will be presented in two poster presentations at the American Society of Hematology (ASH) 2006 Annual Meeting held in Orlando from December 9-12, 2006.
